NVZMY vs. GMAB
NVZMY (Novozymes AS) and GMAB (Genmab A/S) are both stocks. NVZMY operates in Specialty Chemicals (Basic Materials), while GMAB operates in Biotechnology (Healthcare). Over the past 10 years, NVZMY returned 4.37%/yr vs 4.81%/yr for GMAB. Their 0.26 correlation means their historical movements had little consistent relationship.
Performance
NVZMY vs. GMAB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVZMY achieves a 3.46% return, which is significantly higher than GMAB's -6.27% return. Over the past 10 years, NVZMY has underperformed GMAB with an annualized return of 4.37%, while GMAB has yielded a comparatively higher 4.81% annualized return.
NVZMY
- 1D
- -1.20%
- 1M
- -0.09%
- 6M
- 7.36%
- YTD
- 3.46%
- 1Y
- 1.53%
- 3Y*
- 11.45%
- 5Y*
- -2.05%
- 10Y*
- 4.37%
- ALL TIME*
- -2.31%
GMAB
- 1D
- 0.80%
- 1M
- 1.24%
- 6M
- -11.52%
- YTD
- -6.27%
- 1Y
- 32.55%
- 3Y*
- -10.36%
- 5Y*
- -8.52%
- 10Y*
- 4.81%
- ALL TIME*
- 12.59%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
GMAB Genmab A/S | $44.51M | $58.86M | $53.94M |
NVZMY Novozymes AS | $1.59M | $2.04M | $2.52M |
NVZMY vs. GMAB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVZMY Novozymes AS | 3.46% | 14.29% | 3.97% | 12.42% | -38.46% | 46.93% | 18.10% | 10.28% | -20.91% | 69.59% |
GMAB Genmab A/S | -6.27% | 47.58% | -34.45% | -24.87% | 7.13% | -2.71% | 82.09% | 35.54% | -0.61% | -0.04% |
Correlation
The correlation between NVZMY and GMAB is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.26 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.30 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2009 | 0.26 |
The correlation between NVZMY and GMAB shifts across timeframes, from 0.20 (1 year) to 0.31 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
NVZMY:
$30.32B
GMAB:
$17.72B
NVZMY:
€1.28
GMAB:
$4.06
NVZMY:
44.00
GMAB:
7.11
NVZMY:
2.38
GMAB:
2.10
NVZMY:
2.41
GMAB:
3.24
NVZMY:
€11.07B
GMAB:
$8.84B
NVZMY:
€5.79B
GMAB:
$8.27B
NVZMY:
€3.39B
GMAB:
$3.81B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVZMY vs. GMAB — Risk / Return Rank
NVZMY
GMAB
NVZMY vs. GMAB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novozymes AS (NVZMY) and Genmab A/S (GMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVZMY | GMAB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.91 | ||
| Sortino ratioReturn per unit of downside risk | -1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.18 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.09 | 1.03 | -0.93 |
| Martin ratioReturn relative to average drawdown | 0.24 | 2.01 | -1.77 |
Loading charts...
Drawdowns
NVZMY vs. GMAB - Drawdown Comparison
The maximum NVZMY drawdown since its inception was -86.29%, roughly equal to the maximum GMAB drawdown of -84.20%. Use the drawdown chart below to compare losses from any high point for NVZMY and GMAB.
Loading charts...
Drawdown Indicators
| NVZMY | GMAB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.29% | -84.20% | -2.09% |
Max Drawdown (1Y)Largest decline over 1 year | -20.00% | -32.51% | +12.51% |
Max Drawdown (3Y)Largest decline over 3 years | -29.64% | -54.12% | +24.48% |
Max Drawdown (5Y)Largest decline over 5 years | -51.86% | -63.10% | +11.24% |
Max Drawdown (10Y)Largest decline over 10 years | -51.86% | -63.10% | +11.24% |
Current DrawdownCurrent decline from peak | -55.47% | -40.74% | -14.73% |
Average DrawdownAverage peak-to-trough decline | -57.40% | -31.18% | -26.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.68% | 16.57% | -8.89% |
Volatility
NVZMY vs. GMAB - Volatility Comparison
Novozymes AS (NVZMY) has a higher volatility of 9.53% compared to Genmab A/S (GMAB) at 8.00%. This indicates that NVZMY's price experiences larger fluctuations and is considered to be riskier than GMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVZMY | GMAB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.53% | 8.00% | +1.53% |
Volatility (6M)Calculated over the trailing 6-month period | 19.00% | 23.12% | -4.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.50% | 34.25% | -7.75% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.14% | 33.67% | -5.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.11% | 34.95% | -7.84% |
Dividends
NVZMY vs. GMAB - Dividend Comparison
NVZMY's dividend yield for the trailing twelve months is around 1.57%, while GMAB has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GMAB Genmab A/S | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVZMY Novozymes AS | 1.57% | 1.51% | 1.03% | 2.68% | 1.68% | 0.69% | 0.91% | 1.03% | 1.10% | 1.64% | 0.95% | 0.60% |
Financials
NVZMY vs. GMAB - Financials Comparison
This section allows you to compare key financial metrics between Novozymes AS and Genmab A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVZMY vs. GMAB - Profitability Comparison
NVZMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported a gross profit of 644.63M and revenue of 1.14B. Therefore, the gross margin over that period was 56.7%.
GMAB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Genmab A/S reported a gross profit of 834.08M and revenue of 899.32M. Therefore, the gross margin over that period was 92.8%.
NVZMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported an operating income of 272.81M and revenue of 1.14B, resulting in an operating margin of 24.0%.
GMAB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Genmab A/S reported an operating income of 225.83M and revenue of 899.32M, resulting in an operating margin of 25.1%.
NVZMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported a net income of 202.37M and revenue of 1.14B, resulting in a net margin of 17.8%.
GMAB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Genmab A/S reported a net income of 53.20M and revenue of 899.32M, resulting in a net margin of 5.9%.
Frequently Asked Questions
NVZMY and GMAB have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVZMY has higher volatility (9.53%) compared to GMAB (8.00%). In terms of maximum drawdown, NVZMY dropped -86.29% vs GMAB's -84.20%.
GMAB currently has the higher Sharpe Ratio (0.98 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVZMY and GMAB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer